Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Dateline City:
KENILWORTH, N.J.
One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time
New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Samsung Bioepis will present new Phase 3 clinical
data for three investigational immunology biosimilar candidates at the
American College of Rheumatology (ACR) and the Association for
Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San
Francisco, Nov. 7-11.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Allergy & Immunology | Enbrel | Health | Humira | Merck | Pharmaceuticals | Remicade | Rheumatology